Sartorius Stedim Biotech (OTCMKTS:SDMHF) Now Covered by HSBC

Equities research analysts at HSBC began coverage on shares of Sartorius Stedim Biotech (OTCMKTS:SDMHF – Get Rating) in a research note issued to investors on Wednesday, The Fly reports. The firm set a “buy” rating on the stock.

A number of other research analysts have also recently issued reports on SDMHF. UBS Group raised Sartorius Stedim Biotech from a “sell” rating to a “buy” rating in a research note on Monday, May 16th. Morgan Stanley started coverage on Sartorius Stedim Biotech in a research note on Thursday, March 31st. They issued an “equal weight” rating for the company. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the stock. According to MarketBeat, Sartorius Stedim Biotech presently has a consensus rating of “Moderate Buy” and a consensus price target of $550.00.

OTCMKTS SDMHF opened at $288.69 on Wednesday. The stock has a 50-day simple moving average of $329.88 and a 200 day simple moving average of $397.29. Sartorius Stedim Biotech has a 12 month low of $282.50 and a 12 month high of $653.00.

About Sartorius Stedim Biotech (Get Rating)

Sartorius Stedim Biotech SA produces and sells instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products.

Read More